BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma

Jianli Dong, Robert G. Phelps, Rui Qiao, Shen Yao, Outhiriaradjou Benard, Zeev Ronai, Stuart A. Aaronson

Research output: Contribution to journalArticle

256 Scopus citations

Abstract

BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62-72%) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949-954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19-20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997-7000, 2002]. In striking contrast, we found BRAF lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)3883-3885
Number of pages3
JournalCancer Research
Volume63
Issue number14
StatePublished - Jul 15 2003

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., & Aaronson, S. A. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Research, 63(14), 3883-3885.